All Updates

All Updates

icon
Filter
Partnerships
Bridge Biotherapeutics partners with HitGen to accelerate discovery of novel oncology drugs
Precision Medicine
Aug 22, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Geographic expansion
Partnerships
FarmWise partners with RDO Equipment Co. to expand AI-powered weeding technology for vegetable growers
Smart Farming
Yesterday
Management news
Alberta Food Security Inc. receives USD 5 million order for indoor farming technology
Vertical Farming
Yesterday
Partnerships
AutoStore enhances microfulfilment offering with new grid capabilities and multi-temperature solution
Logistics Tech
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Generative AI Applications
Yesterday
Funding
Apptile raises USD 1.2 million in seed funding to develop platform
No-code Software
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Foundation Models
Yesterday
Product updates
SPEE3D demonstrates 3D printing for US Army
Additive Manufacturing
Yesterday
Precision Medicine

Precision Medicine

Aug 22, 2024

Bridge Biotherapeutics partners with HitGen to accelerate discovery of novel oncology drugs

Partnerships

  • Bridge Biotherapeutics has partnered with Chinese drug discovery company HitGen to speed up the development of novel anticancer drugs. Financial and other details of the new agreement were undisclosed.

  • The partnership aims to leverage the companies’ expertise, technology, and resources to expand Bridge's oncology portfolio, based on the potent anticancer compounds from HitGen’s vast DNA-encoded library (DEL). The collaboration is expected to generate effective oncology treatments for genetically mutated forms of cancers that are considered challenging to address. 

  • Bridge Biotherapeutics, headquartered in South Korea with offices in the US and China, is a clinical-stage biotechnology company focused on developing novel therapeutics for high unmet medical needs in cancer, fibrosis, and inflammatory diseases. The company's lead candidate, BBT-877, is a novel autotaxin inhibitor being evaluated in a Phase IIa trial for idiopathic pulmonary fibrosis (IPF). Bridge Biotherapeutics is also advancing BBT-207, a fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), currently in trials for non-small-cell lung cancer (NSCLC) with EGFR C797S mutations.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.